Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: A prospective study

American Journal of Medicine

Volumn 113, Issue 3, 2002, Pages 188-193

  Park, Yong Beom ^a   Choi, Hyon K ^c   Kim, Min Young ^b   Lee, Won Ki ^a   Song, Jungsik ^a   Kim, Dong Kee ^b   Lee, Soo Kon ^a,b  

^a Korea University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; APOLIPOPROTEIN A1; CORTICOSTEROID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COLLEGE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LIPID ANALYSIS; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RHEUMATOID ARTHRITIS; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; METHOTREXATE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 0037102007     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01186-5     Document Type: Article

References (36)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 340:1999;115-126.
2. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979.
3. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:2000;836-843.
4. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 343:2000;1148-1155.
5. Danesh J., Muir J., Wong Y.K., et al. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J. 20:1999;954-959.
6. Hak A.E., Stehouwer C.D., Bots M.L., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 19:1999;1986-1991.
7. Tracy R.P. Inflammation markers and coronary heart disease. Curr Opin Lipidol. 10:1999;435-441.
8. Symmons D.P., Jones M.A., Scott D.L., Prior P. Long-term mortality outcome in patients with rheumatoid arthritis early presenters continue to do well . J Rheumatol. 25:1998;1072-1077.
9. Wallberg-Jonsson S., Ohman M.L., Dahlqvist S.R. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 24:1997;445-451.
10. Mutru O., Laakso M., Isomaki H., Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. BMJ. 290:1985;1797-1799.
11. Isomaki H.A., Mutru O., Koota K. Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol. 4:1975;205-208.
12. Zonana-Nacach A., Barr S.G., Magder L.S., Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 43:2000;1801-1808.
13. Park Y.B., Lee S.K., Lee W.K., et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol. 26:1999;1701-1704.
14. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:1988;315-324.
15. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines . Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum. 39:1996;713-722.
16. Felson D.T., Anderson J.J., Boers M., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38:1995;727-735.
17. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
18. Blumenthal R.S. Statins effective antiatherosclerotic therapy . Am Heart J. 139:2000;577-583.
19. Martin-Jadraque R., Tato F., Mostaza J.M., et al. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. Arch Intern Med. 156:1996;1081-1088.
20. Cabana V.G., Gidding S.S., Getz G.S., et al. Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res. 42:1997;651-655.
21. Borba E.F., Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus influence of disease, activity, and anticardiolipin antibodies . Lupus. 6:1997;533-539.
22. Orem A., Deger O., Memis O., et al. Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behcet's disease. Ann Rheum Dis. 54:1995;726-729.
23. Chou C.T., Chao P.M. Lipid abnormalities in Taiwan Aborigines with gout. Metabolism. 48:1999;131-133.
24. Gidding S.S., Stone N.J., Bookstein L.C., et al. Month-to-month variability of lipids, lipoproteins, and apolipoproteins and the impact of acute infection in adolescents. J Pediatr. 133:1998;242-246.
25. Blackman J.D., Cabana V.G., Mazzone T. The acute-phase response and associated lipoprotein abnormalities accompanying lymphoma. J Intern Med. 233:1993;201-204.
26. Cabana V.G., Lukens J.R., Rice K.S., et al. HDL content and composition in acute phase response in three species triglyceride enrichment of HDL a factor in its decrease . J Lipid Res. 37:1996;2662-2674.
27. Hosoai H., Webb N.R., Glick J.M., et al. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J Lipid Res. 40:1999;648-653.
28. Stefanick M.L., Mackey S., Sheehan M., et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 339:1998;12-20.
29. Cauley J.A., Kriska A.M., LaPorte R.E., et al. A two year randomized exercise trial in older women effects on HDL-cholesterol . Atherosclerosis. 66:1987;247-258.
30. Thompson C.E., Thomas T.R., Araujo J., et al. Response of HDL cholesterol, apolipoprotein A-I, and LCAT to exercise withdrawal. Atherosclerosis. 54:1985;65-73.
31. Badolato R., Oppenheim J.J. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum. 26:1996;526-538.
32. Feldmann M., Maini R.N. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 38:1999;3-7.
33. Cutolo M., Sulli A., Villaggio B., et al. Relations between steroid hormones and cytokines in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 57:1998;573-577.
34. Carroll G., Bell M., Wang H., et al. Antagonism of the IL-6 cytokine subfamily - a potential strategy for more effective therapy in rheumatoid arthritis. Inflamm Res. 47:1998;1-7.
35. Pasceri V., Yeh E.T. A tale of two diseases atherosclerosis and rheumatoid arthritis . Circulation. 100:1999;2124-2126.
36. Wolfe F., Hawley D.J., Anderson J. Inflammation as measured by the ESR predicts cardiovascular mortality across all rheumatic disorders a 25-year prospective study of 5,822 patients. Arthritis Rheum. 42:(suppl):1999;S299.